|
US6322789B1
(en)
|
1991-08-26 |
2001-11-27 |
Epimmune, Inc. |
HLA-restricted hepatitis B virus CTL epitopes
|
|
JPH10503379A
(ja)
*
|
1994-07-29 |
1998-03-31 |
デイド・インターナショナル・インコーポレーテッド |
Ｍｈｃ複合体およびその用途
|
|
US5635363A
(en)
|
1995-02-28 |
1997-06-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
|
|
US5869270A
(en)
|
1996-01-31 |
1999-02-09 |
Sunol Molecular Corporation |
Single chain MHC complexes and uses thereof
|
|
US6211342B1
(en)
|
1996-07-18 |
2001-04-03 |
Children's Hospital Medical Center |
Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function
|
|
US20050003431A1
(en)
|
1996-08-16 |
2005-01-06 |
Wucherpfennig Kai W. |
Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
|
|
US6218363B1
(en)
|
1996-08-28 |
2001-04-17 |
Thomas Jefferson University |
MHC peptides and methods of use
|
|
EP0979239B1
(en)
|
1997-02-13 |
2006-10-18 |
The Regents Of The University Of California |
Prevention and treatment of hepatocellular cancer
|
|
US7098306B2
(en)
|
1997-02-13 |
2006-08-29 |
The Regents Of The University Of California |
Method and compositions for treating hepatocellular cancer
|
|
US6268411B1
(en)
|
1997-09-11 |
2001-07-31 |
The Johns Hopkins University |
Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
|
|
ES2357960T3
(es)
|
1997-05-08 |
2011-05-04 |
Oncothyreon Inc. |
Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos.
|
|
US20030007978A1
(en)
|
1997-09-16 |
2003-01-09 |
Burrows Gregory G. |
Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
|
|
US6696304B1
(en)
|
1999-02-24 |
2004-02-24 |
Luminex Corporation |
Particulate solid phase immobilized protein quantitation
|
|
KR100903710B1
(ko)
|
1999-04-30 |
2009-06-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
돌연변이체 인간 ｃｄ80, 이를 포함하는 조성물, 및 이를제조하고 이용하는 방법
|
|
US20020006664A1
(en)
|
1999-09-17 |
2002-01-17 |
Sabatini David M. |
Arrayed transfection method and uses related thereto
|
|
AU2000243137A1
(en)
*
|
2000-04-20 |
2001-11-07 |
Salvatore Albani |
Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
|
|
CA2410642A1
(en)
|
2000-05-25 |
2001-11-29 |
Sunol Molecular Corporation |
Modulation of t-cell receptor interactions
|
|
WO2004029197A2
(en)
|
2001-06-22 |
2004-04-08 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
US20020122820A1
(en)
|
2001-01-16 |
2002-09-05 |
Hildebrand William H. |
Soluble MHC artificial antigen presenting cells
|
|
US6800748B2
(en)
|
2001-01-25 |
2004-10-05 |
Large Scale Biology Corporation |
Cytoplasmic inhibition of gene expression and expression of a foreign protein in a monocot plant by a plant viral vector
|
|
ES2747357T3
(es)
|
2001-03-14 |
2020-03-10 |
Dako Denmark As |
Construcciones de moléculas MHC y sus usos para el diagnóstico y terapia
|
|
US6811785B2
(en)
*
|
2001-05-07 |
2004-11-02 |
Mount Sinai School Of Medicine Of New York University |
Multivalent MHC class II—peptide chimeras
|
|
WO2002093129A2
(en)
|
2001-05-15 |
2002-11-21 |
University Of Medicine & Dentistry Of New Jersey |
Methods for analyzing interactions between proteins in live and intact cells
|
|
WO2002099070A2
(en)
|
2001-06-04 |
2002-12-12 |
Corixa Corporation |
Compositions and methods for high-level, large-scale production of recombinant proteins
|
|
US20030017134A1
(en)
|
2001-06-19 |
2003-01-23 |
Technion Research And Development Foundation Ltd. |
Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
|
|
WO2003006632A2
(en)
|
2001-07-12 |
2003-01-23 |
Canvac |
Methods and compisitions for activation human t cells in vitro
|
|
US20040038349A1
(en)
|
2001-07-27 |
2004-02-26 |
Hilbert David M. |
Heteromultimeric TNF ligand family members
|
|
PT1454138E
(pt)
|
2001-12-04 |
2012-03-28 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
AU2002316574B2
(en)
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
|
US8895020B2
(en)
|
2002-04-19 |
2014-11-25 |
Washington University |
Single chain trimers and uses therefor
|
|
DE60332358D1
(de)
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
US7432351B1
(en)
|
2002-10-04 |
2008-10-07 |
Mayo Foundation For Medical Education And Research |
B7-H1 variants
|
|
WO2004076488A1
(en)
|
2003-02-27 |
2004-09-10 |
Theravision Gmbh |
A molecule which binds cd80 and cd86
|
|
US20050042641A1
(en)
|
2003-05-27 |
2005-02-24 |
Cold Spring Harbor Laboratory |
In vivo high throughput selection of RNAi probes
|
|
US7696306B2
(en)
|
2003-07-11 |
2010-04-13 |
Board of Agents of the University of Nebraska |
Compositions and methods for preventing or treating cancer
|
|
EP1675607B1
(en)
|
2003-09-05 |
2015-10-21 |
Oregon Health & Science University |
Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
|
|
US7470513B2
(en)
|
2003-11-10 |
2008-12-30 |
Academia Sinica |
Risk assessment for adverse drug reactions
|
|
BRPI0508470A
(pt)
|
2004-03-05 |
2007-07-31 |
Chiron Corp |
sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
|
|
DE102004014983A1
(de)
|
2004-03-26 |
2005-10-20 |
Univ Stuttgart |
Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
|
|
AU2005247950B2
(en)
|
2004-05-27 |
2012-02-02 |
Receptor Logic, Inc. |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
|
US7670595B2
(en)
|
2004-06-28 |
2010-03-02 |
Merck Patent Gmbh |
Fc-interferon-beta fusion proteins
|
|
CA2523032A1
(en)
|
2005-10-07 |
2007-04-07 |
Immunovaccine Technologies Inc. |
Vaccines for cancer therapy
|
|
US7943133B2
(en)
|
2006-02-02 |
2011-05-17 |
Boston Biocom Llc |
Mesothelin antibody protein fusions and methods of use
|
|
US8518697B2
(en)
|
2006-04-04 |
2013-08-27 |
Washington University |
Single chain trimers and uses therefor
|
|
US7977457B2
(en)
|
2006-05-19 |
2011-07-12 |
Teva Pharmaceutical Industries Ltd. |
Fusion proteins, uses thereof and processes for producing same
|
|
EP1889851A1
(en)
|
2006-08-18 |
2008-02-20 |
Charite Universitätsmedizin-Berlin |
PAX2 and PAX8 as targets for immunologic and molecular tumour treatment strategies
|
|
US8992937B2
(en)
|
2006-08-28 |
2015-03-31 |
Washington University |
Disulfide trap MHC class I molecules and uses therefor
|
|
CA2670658A1
(en)
|
2006-12-28 |
2008-07-10 |
International Institute Of Cancer Immunology, Inc. |
Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
|
|
EP2129389B1
(en)
|
2007-02-15 |
2014-10-08 |
MannKind Corporation |
A method for enhancing t cell response
|
|
WO2008113970A2
(en)
|
2007-03-16 |
2008-09-25 |
Ucl Business Plc |
Peptides
|
|
EP2361930A3
(en)
|
2007-03-26 |
2011-10-26 |
Dako Denmark A/S |
Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
|
|
JP5444553B2
(ja)
|
2007-04-27 |
2014-03-19 |
フェネックス インコーポレイテッド |
微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および／または質が改善されている特定の株を同定する方法
|
|
US8933197B2
(en)
|
2007-08-15 |
2015-01-13 |
Amunix Operating Inc. |
Compositions comprising modified biologically active polypeptides
|
|
US8926961B2
(en)
|
2007-10-03 |
2015-01-06 |
Board Of Trustees Of The University Of Arkansas |
HPV E6 protein T cell epitopes and uses thereof
|
|
CN101418309B
(zh)
|
2007-10-23 |
2011-05-04 |
中国农业科学院上海兽医研究所 |
柔嫩艾美耳球虫蛋白质二硫键异构酶基因的克隆、表达及应用
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
TW201008574A
(en)
|
2008-08-19 |
2010-03-01 |
Oncotherapy Science Inc |
INHBB epitope peptides and vaccines containing the same
|
|
WO2010037395A2
(en)
|
2008-10-01 |
2010-04-08 |
Dako Denmark A/S |
Mhc multimers in cancer vaccines and immune monitoring
|
|
EP2184070A1
(en)
|
2008-11-07 |
2010-05-12 |
Hla-G Technologies |
HLA-G proteins and pharmaceutical uses thereof
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
CA2748314C
(en)
|
2009-02-03 |
2018-10-02 |
Amunix Operating Inc. |
Extended recombinant polypeptides and compositions comprising same
|
|
EP2445935B1
(en)
|
2009-06-25 |
2015-07-01 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Multimeric polypeptides of hla-g including alpha1-alpha3 monomers and pharmaceutical uses thereof
|
|
WO2011066342A2
(en)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Simultaneous inhibition of pd-l1/pd-l2
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
WO2012007951A1
(en)
|
2010-07-15 |
2012-01-19 |
Technion Research & Development Foundation Ltd. |
Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
|
|
CN107880136B
(zh)
|
2010-09-21 |
2021-11-12 |
阿尔托生物科学有限公司 |
多聚体il-15可溶性融合分子与其制造与使用方法
|
|
US9428567B2
(en)
|
2010-12-22 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of interleukin-2 receptor
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EA201400046A1
(ru)
|
2011-06-22 |
2014-07-30 |
Ф. Хоффманн-Ля Рош Аг |
Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов
|
|
MY180616A
(en)
|
2011-06-30 |
2020-12-03 |
Genzyme Corp |
Inhibitors of t-cell activation
|
|
US9494588B2
(en)
|
2011-08-30 |
2016-11-15 |
Jacobs University Bremen Ggmbh |
Gene coded for a MHC class I molecule, plasmid, expression system protein, multimer, reagent and kit to analyze a T cell frequency
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
CA2861206C
(en)
|
2012-01-13 |
2021-07-06 |
Richard J. O'reilly |
Immunogenic wt-1 peptides and methods of use thereof
|
|
CA2863658C
(en)
|
2012-02-03 |
2023-03-14 |
Emory University |
Immunostimulatory compositions, particles, and uses related thereto
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
JP2015537043A
(ja)
|
2012-11-30 |
2015-12-24 |
ロシュ グリクアート アーゲー |
多機能タンパク質を含むがん細胞標的化ｍｈｃクラスｉを用いた循環性ウイルス特異的細胞傷害性ｔ細胞によるがん細胞の除去
|
|
EP3640375A3
(en)
|
2012-12-11 |
2020-07-29 |
Albert Einstein College of Medicine |
Methods for high throughput receptor/ligand identification
|
|
CA2889788A1
(en)
|
2012-12-21 |
2014-06-26 |
F. Hoffmann-La Roche Ag |
Disulfide-linked multivalent mhc class i comprising multi-function proteins
|
|
US10815273B2
(en)
|
2013-01-15 |
2020-10-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic WT-1 peptides and methods of use thereof
|
|
EP3769782A1
(en)
|
2013-01-15 |
2021-01-27 |
Memorial Sloan Kettering Cancer Center |
Immunogenic wt-1 peptides and methods of use thereof
|
|
EP2948475A2
(en)
|
2013-01-23 |
2015-12-02 |
AbbVie Inc. |
Methods and compositions for modulating an immune response
|
|
CA2902739C
(en)
|
2013-03-15 |
2022-11-22 |
Xencor, Inc. |
Heterodimeric proteins
|
|
EP2968450A4
(en)
|
2013-03-15 |
2016-10-26 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
|
MY171854A
(en)
|
2013-03-29 |
2019-11-05 |
Sumitomo Dainippon Pharma Co Ltd |
Wt1 antigen peptide conjugate vaccine
|
|
AU2014266396A1
(en)
|
2013-05-13 |
2015-12-03 |
International Institute Of Cancer Immunology, Inc. |
Method for predicting clinical effect of immunotherapy
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
JP6595988B2
(ja)
|
2013-07-19 |
2019-10-23 |
ヴィブ ブイゼットダブリュー |
ターゲットされる修飾ｔｎｆファミリーメンバー
|
|
SG11201605632SA
(en)
|
2014-01-21 |
2016-08-30 |
Einstein Coll Med |
Cellular platform for rapid and comprehensive t-cell immunomonitoring
|
|
US20160152725A1
(en)
|
2014-02-25 |
2016-06-02 |
Memorial Sloan-Kettering Cancer Center |
Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
|
|
EP3112378B1
(en)
|
2014-02-26 |
2020-06-24 |
Tella, Inc. |
Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
PL3157552T3
(pl)
|
2014-06-18 |
2020-05-18 |
Albert Einstein College Of Medicine |
Polipeptydy syntac i ich zastosowania
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
GB2538666A
(en)
|
2014-07-21 |
2016-11-23 |
Delinia Inc |
Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
JP6800141B2
(ja)
|
2014-08-12 |
2020-12-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
|
|
WO2016029043A1
(en)
|
2014-08-21 |
2016-02-25 |
The General Hospital Corporation |
Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
|
|
MY193723A
(en)
|
2014-08-29 |
2022-10-27 |
Hoffmann La Roche |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
CA2978186A1
(en)
|
2015-03-05 |
2016-09-09 |
Fred Hutchinson Cancer Research Center |
Immunomodulatory fusion proteins and uses thereof
|
|
CN115873129A
(zh)
|
2015-03-23 |
2023-03-31 |
约翰·霍普金斯大学 |
由体细胞突变基因编码的hla限制性表位
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
ES3055030T3
(en)
|
2015-05-06 |
2026-02-09 |
Uti Lp |
Nanoparticle compositions for sustained therapy
|
|
EP3322715B1
(en)
|
2015-07-14 |
2023-10-18 |
BioNTech SE |
Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof
|
|
EP3328377A4
(en)
|
2015-07-31 |
2019-03-13 |
Tarveda Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
|
|
WO2017029389A1
(en)
*
|
2015-08-20 |
2017-02-23 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
B7-h1 fusion polypeptides for treating and preventing organ failure
|
|
CN106565836B
(zh)
|
2015-10-10 |
2020-08-18 |
中国科学院广州生物医药与健康研究院 |
高亲和力的可溶性pdl-1分子
|
|
LT3377516T
(lt)
|
2015-11-20 |
2022-09-26 |
Memorial Sloan Kettering Cancer Center |
Kompozicija vėžiui gydyti
|
|
US20190365656A1
(en)
|
2016-01-04 |
2019-12-05 |
Cour Pharmaceuticals Development Company, Inc. |
Particles encapsulating fusion proteins containing linked epitopes
|
|
EP3408279A1
(en)
|
2016-01-27 |
2018-12-05 |
CSL Behring Lengnau AG |
Recombinant igg fc multimers
|
|
CA3014458A1
(en)
|
2016-03-02 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
AU2017225787B2
(en)
*
|
2016-03-03 |
2021-09-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR102687530B1
(ko)
|
2016-05-04 |
2024-07-25 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
CA3019005A1
(en)
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR20190044029A
(ko)
*
|
2016-05-18 |
2019-04-29 |
알버트 아인슈타인 컬리지 오브 메디슨, 인크. |
변이체 pd-l1 폴리펩타이드, t-세포 조절 다량체 폴리펩타이드 및 이들의 사용 방법
|
|
MX2019005497A
(es)
|
2016-11-09 |
2019-11-18 |
Uti Lp |
Moleculas de pmhc de clase ii recombinantes.
|
|
CN116970059A
(zh)
|
2016-12-22 |
2023-10-31 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
IL269000B2
(en)
|
2017-03-15 |
2024-06-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
|
AU2018236461B2
(en)
|
2017-03-17 |
2025-03-27 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
CN110945120B
(zh)
*
|
2017-04-07 |
2025-04-18 |
优迪有限合伙公司 |
测量纳米药物中受体-配体相互作用的效力的测定
|
|
EP3446702A1
(en)
|
2017-08-23 |
2019-02-27 |
Medizinische Hochschule Hannover |
Synthetic vaccine
|
|
TW201925235A
(zh)
*
|
2017-09-07 |
2019-07-01 |
美商信號生物製藥公司 |
具有化學結合位點之抗原呈現多肽及其使用方法
|
|
EP3678677A4
(en)
*
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
TW201920249A
(zh)
|
2017-09-07 |
2019-06-01 |
美商信號生物製藥公司 |
具有結合位點之t細胞調節多聚體多肽及其使用方法
|
|
EP3678691A4
(en)
|
2017-09-07 |
2021-06-09 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
BR112020006643A2
(pt)
|
2017-10-03 |
2020-09-24 |
Juno Therapeutics Inc |
moléculas de ligação específica ao hpv
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019162937A1
(en)
|
2018-02-20 |
2019-08-29 |
Technion Research & Development Foundation Limited |
Immunotherapeutic composition for the treatment of cancer
|
|
DE102018122546B3
(de)
*
|
2018-09-14 |
2019-12-05 |
Immatics Biotechnologies Gmbh |
Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
|
|
WO2020132366A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
AU2019401183A1
(en)
*
|
2018-12-19 |
2021-08-12 |
Cue Biopharma, Inc. |
Multimeric T-cell modulatory polypeptides and methods of use thereof
|
|
EP3897690A4
(en)
|
2018-12-19 |
2022-09-28 |
Cue Biopharma, Inc. |
T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
WO2020132365A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
CN118852456A
(zh)
|
2019-05-29 |
2024-10-29 |
Cue生物制药股份有限公司 |
多聚体t细胞调节多肽及其使用方法
|
|
AU2020287373B2
(en)
|
2019-06-05 |
2026-01-29 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
|
|
JP2022536581A
(ja)
|
2019-06-19 |
2022-08-18 |
キュー バイオファーマ， インコーポレイテッド |
多量体ｔ細胞調節性ポリペプチド及びその使用方法
|
|
WO2021055594A1
(en)
|
2019-09-20 |
2021-03-25 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
EP4048402A4
(en)
|
2019-10-23 |
2023-11-22 |
Cue Biopharma, Inc. |
MODIFIED CYTOTOXIC T CELLS AND METHOD OF USE THEREOF
|
|
WO2021081239A1
(en)
|
2019-10-23 |
2021-04-29 |
Cue Biopharma, Inc. |
T-cell modulatory chimeric molecules and methods of use thereof
|
|
JP7726881B2
(ja)
|
2019-12-02 |
2025-08-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用
|
|
BR112022012112A2
(pt)
|
2019-12-20 |
2022-09-06 |
Regeneron Pharma |
Agonistas de il2 e métodos de uso dos mesmos
|
|
KR20220147106A
(ko)
|
2020-02-28 |
2022-11-02 |
도쿠리츠다이가쿠호징 가나자와다이가쿠 |
항원 제시 세포 외 소포, 그것을 포함하는 조성물, 및 그들을 제조하기 위한 방법
|
|
US20230117521A1
(en)
|
2020-03-25 |
2023-04-20 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
GB202005617D0
(en)
|
2020-04-17 |
2020-06-03 |
Adaptimmune Ltd |
Improved t cell manufacturing process
|
|
TW202208395A
(zh)
|
2020-05-12 |
2022-03-01 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
CN113823723A
(zh)
|
2020-06-18 |
2021-12-21 |
光宝光电(常州)有限公司 |
发光二极管封装结构
|
|
EP4182465A4
(en)
|
2020-07-14 |
2024-08-07 |
Cue Biopharma, Inc. |
T-CELL MODULATORY POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
EP4232071A4
(en)
|
2020-10-23 |
2024-08-28 |
Asher Biotherapeutics, Inc. |
FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
|
|
CA3174142A1
(en)
*
|
2020-11-06 |
2022-05-12 |
Ronald D. Seidel Iii |
T-cell modulatory polypeptides with conjugation sites and methods of use thereof
|
|
CN116829194A
(zh)
|
2020-12-09 |
2023-09-29 |
亚设生物治疗公司 |
用于工程化细胞疗法的靶向细胞因子构建体
|
|
WO2022125694A1
(en)
|
2020-12-09 |
2022-06-16 |
Asher Biotherapeutics, Inc. |
Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
|
|
JP2024512470A
(ja)
|
2021-03-19 |
2024-03-19 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節ポリペプチド及びその使用方法
|